ATE260644T1 - Peptid/lipid-komplexbildung durch co- lyophilisation - Google Patents
Peptid/lipid-komplexbildung durch co- lyophilisationInfo
- Publication number
- ATE260644T1 ATE260644T1 AT98950743T AT98950743T ATE260644T1 AT E260644 T1 ATE260644 T1 AT E260644T1 AT 98950743 T AT98950743 T AT 98950743T AT 98950743 T AT98950743 T AT 98950743T AT E260644 T1 ATE260644 T1 AT E260644T1
- Authority
- AT
- Austria
- Prior art keywords
- peptide
- lyophilization
- complex formation
- lipid complex
- lipids
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 230000009918 complex formation Effects 0.000 title 1
- 238000004108 freeze drying Methods 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/942,597 US6287590B1 (en) | 1997-10-02 | 1997-10-02 | Peptide/lipid complex formation by co-lyophilization |
PCT/US1998/020330 WO1999017740A1 (en) | 1997-10-02 | 1998-09-28 | Peptide/lipid complex formation by co-lyophilization |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE260644T1 true ATE260644T1 (de) | 2004-03-15 |
Family
ID=25478329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98950743T ATE260644T1 (de) | 1997-10-02 | 1998-09-28 | Peptid/lipid-komplexbildung durch co- lyophilisation |
Country Status (20)
Country | Link |
---|---|
US (4) | US6287590B1 (de) |
EP (2) | EP1019025B1 (de) |
JP (1) | JP2001522781A (de) |
KR (1) | KR100588241B1 (de) |
CN (1) | CN100415210C (de) |
AT (1) | ATE260644T1 (de) |
AU (2) | AU749344B2 (de) |
CA (1) | CA2305704C (de) |
DE (1) | DE69822176T2 (de) |
DK (1) | DK1019025T3 (de) |
ES (1) | ES2217591T3 (de) |
HU (1) | HUP0003930A3 (de) |
IL (1) | IL135322A (de) |
NO (1) | NO329155B1 (de) |
NZ (1) | NZ503721A (de) |
PL (1) | PL196579B1 (de) |
PT (1) | PT1019025E (de) |
RU (1) | RU2224506C2 (de) |
UA (1) | UA71551C2 (de) |
WO (1) | WO1999017740A1 (de) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5746223A (en) * | 1996-10-11 | 1998-05-05 | Williams; Kevin Jon | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis |
US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
DE19954843C2 (de) * | 1999-11-09 | 2003-11-20 | Novosom Ag | Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren Verwendung |
US6514523B1 (en) | 2000-02-14 | 2003-02-04 | Ottawa Heart Institute Research Corporation | Carrier particles for drug delivery and process for preparation |
GB0121171D0 (en) * | 2001-08-31 | 2001-10-24 | Glaxosmithkline Biolog Sa | Vaccine |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US7144862B2 (en) * | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
ES2309228T3 (es) * | 2001-08-23 | 2008-12-16 | Westgate Biological Limited | Uso de apoproteinas del suero lacteo en la profilaxis o el tratamiento de la infeccion microbiana o virica. |
US7470659B2 (en) | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
EP1461028A4 (de) * | 2001-12-07 | 2007-07-25 | Univ California | Behandlung für altersbezogene makuladegeneration |
US20030229062A1 (en) * | 2001-12-07 | 2003-12-11 | The Regents Of The University Of California | Treatments for age-related macular degeneration (AMD) |
US20040009216A1 (en) * | 2002-04-05 | 2004-01-15 | Rodrigueza Wendi V. | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
US6930085B2 (en) | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
NL1020962C2 (nl) * | 2002-06-28 | 2003-12-30 | Tno | Therapie en prognose/monitoring bij sepsis en septische shock. |
US10517883B2 (en) | 2003-06-27 | 2019-12-31 | Zuli Holdings Ltd. | Method of treating acute myocardial infarction |
US20060051407A1 (en) * | 2003-06-27 | 2006-03-09 | Yoram Richter | Method of treating ischemia-reperfusion injury |
PE20050438A1 (es) * | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
US20060019870A1 (en) * | 2004-01-28 | 2006-01-26 | O'donnell Francis E Jr | Apoprotein cochleate compositions |
JP4617458B2 (ja) * | 2004-02-10 | 2011-01-26 | 財団法人ヒューマンサイエンス振興財団 | 中空糸透析カラムを利用したリポソームの製造方法 |
SE0401942D0 (sv) * | 2004-07-28 | 2004-07-28 | Lipopeptide Ab | New antimicrobial peptide complexes |
US20060205669A1 (en) * | 2004-09-16 | 2006-09-14 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
US7464012B2 (en) * | 2004-12-10 | 2008-12-09 | L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude | Simplified process simulator |
US7582312B2 (en) * | 2004-11-15 | 2009-09-01 | Discovery Laboratories, Inc. | Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof |
AU2005314043A1 (en) | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
KR20070112289A (ko) * | 2005-03-16 | 2007-11-22 | 프로사이트 코포레이션 | 노화 또는 광손상된 피부를 예방하고 치료하기 위한 방법및 조성물 |
US8206750B2 (en) * | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
AU2006242651B2 (en) * | 2005-04-29 | 2013-05-16 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US20070254832A1 (en) * | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
EP2537526A1 (de) | 2006-06-01 | 2012-12-26 | Institut de Cardiologie de Montréal | Verfahren und Verbindung zur Behandlung von Klappenstenose |
WO2007149355A2 (en) * | 2006-06-16 | 2007-12-27 | Lipid Sciences, Inc. | Novel peptides that promote lipid efflux |
US20080227686A1 (en) * | 2006-06-16 | 2008-09-18 | Lipid Sciences, Inc. | Novel Peptides that Promote Lipid Efflux |
US20080206142A1 (en) * | 2006-06-16 | 2008-08-28 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
AU2007284801A1 (en) | 2006-08-08 | 2008-02-21 | The Regents Of The University Of Californina | Salicylanilides enhance oral delivery of therapeutic peptides |
WO2008039843A2 (en) * | 2006-09-26 | 2008-04-03 | Lipid Sciences, Inc. | Novel peptides that promote lipid efflux |
RU2443412C2 (ru) * | 2006-10-06 | 2012-02-27 | Скил Текнолоджи Гмбх | Высушенные восстановленные везикулы для фармацевтического применения |
KR100817024B1 (ko) | 2006-11-09 | 2008-03-26 | 재단법인 목암생명공학연구소 | 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물 |
KR101507188B1 (ko) | 2007-06-27 | 2015-03-30 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 펩티드 티로시나제 억제제 및 그의 용도 |
EP2173370B1 (de) * | 2007-06-27 | 2015-10-21 | The Board of Trustees of the Leland Stanford Junior University | Oligopeptid-tyrosinase-inhibitoren und ihre verwendungen |
AU2008296478B9 (en) | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
WO2010083611A1 (en) | 2009-01-23 | 2010-07-29 | Institut De Cardiologie De Montreal | Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex |
PT2396017E (pt) | 2009-02-16 | 2015-10-22 | Cerenis Therapeutics Holding Sa | Miméticos da apolipoproteína a-i |
KR101131202B1 (ko) * | 2009-02-23 | 2012-04-05 | (주)에이피테크놀로지 | 난용성 약물 나노복합체의 제조방법 |
WO2011002258A2 (ko) * | 2009-07-02 | 2011-01-06 | 한양대학교 산학협력단 | 아르기닌 기제 양친성 펩티드 마이셀 |
US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
US20130137628A1 (en) | 2010-05-11 | 2013-05-30 | Esperion Therapeutics, Inc. | Dimeric Oxidation-Resistant Apolipoprotein A1 Variants |
BR112013004397A2 (pt) | 2010-08-30 | 2017-06-27 | Hoffmann La Roche | método para produzir uma partícula de lipídio, a partícula de lipídio em si e seu uso |
DK2767546T3 (en) | 2011-02-07 | 2019-02-04 | Cerenis Therapeutics Holding Sa | Lipoprotein complexes and their preparation and uses |
RU2457864C1 (ru) * | 2011-07-28 | 2012-08-10 | Общество с ограниченной ответственностью "Научно-производственная компания "ФАРМАСОФТ" (ООО "НПК "ФАРМАСОФТ") | Гель, обладающий противовоспалительным, иммунотропным, противоаллергическим и ранозаживляющим действием |
US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
AU2014228815B2 (en) | 2013-03-15 | 2019-04-18 | The Regents Of The University Of California | Peptides having reduced toxicity that stimulate cholesterol efflux |
CN103860470A (zh) * | 2014-03-05 | 2014-06-18 | 贵州中泰生物科技有限公司 | 一种口服高密度脂蛋白脂质体的制备方法 |
KR20170003611A (ko) | 2014-05-02 | 2017-01-09 | 세레니스 쎄라퓨틱스 홀딩 에스에이 | Hdl 요법 마커 |
US10653747B2 (en) | 2014-07-31 | 2020-05-19 | Uab Research Foundation | ApoE mimetic peptides and higher potency to clear plasma cholesterol |
EP3213755B1 (de) * | 2014-10-30 | 2020-06-24 | Delta-Fly Pharma, Inc. | Neue verfahren zur herstellung von lipoplex zur lokalen verabreichung und antitumormedikament mit lipoplex |
US11642419B2 (en) | 2015-03-25 | 2023-05-09 | The Regents Of The University Of Michigan | Compositions and methods for treating cardiovascular related disorders |
US20160346219A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
EP3319980B8 (de) | 2015-07-10 | 2021-11-03 | Peptinovo Biopharma Inc. | Formulierungen zur verbesserung der wirksamkeit von hydrophoben arzneimitteln |
WO2018019911A1 (en) | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sarl | Therapeutic combinations to treat red blood cell disorders |
CN109661265A (zh) * | 2016-08-31 | 2019-04-19 | 丘比株式会社 | 蛋黄磷脂组合物及其制造方法、以及使用该蛋黄磷脂组合物的脂肪乳剂及脂解制剂 |
KR102039661B1 (ko) | 2017-07-28 | 2019-11-01 | 경북대학교 산학협력단 | HDL-ApoM-S1P를 유효성분으로 포함하는 퇴행성뇌질환의 예방 또는 치료용 약학적 조성물 |
WO2019030574A1 (en) * | 2017-08-10 | 2019-02-14 | Cerenis Therapeutics Holding | CARGOMÈRES |
CN111249451B (zh) * | 2020-01-20 | 2022-11-04 | 成都医学院 | 一种糖脂类抗原注射液及其制备方法 |
CN112034175A (zh) * | 2020-04-03 | 2020-12-04 | 苏州艾可瑞斯生物科技有限公司 | 一种ApoA-II、ApoC-II检测混合质控品及其制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH621479A5 (de) | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
CA1173360A (en) | 1979-06-22 | 1984-08-28 | Jurg Schrank | Pharmaceutical preparations |
FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
US4857319A (en) | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
US5178875A (en) * | 1991-01-14 | 1993-01-12 | The Board Of Regents, The University Of Texas System | Liposomal-polyene preliposomal powder and method for its preparation |
CA1335077C (en) * | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
US5077057A (en) * | 1989-04-05 | 1991-12-31 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US5753258A (en) * | 1990-10-19 | 1998-05-19 | University Of Florida | Artificial viral envelopes |
EP0644897B1 (de) * | 1992-06-12 | 1998-09-16 | N.V. Innogenetics S.A. | Peptide und Proteine, Verfahren zur Ihren Herstellung und die Verwendung als Cholesterol-Annehmer |
US5785984A (en) * | 1993-02-05 | 1998-07-28 | Kao Corporation | Taste-modifying method and bitterness-decreasing method |
US5534241A (en) * | 1993-07-23 | 1996-07-09 | Torchilin; Vladimir P. | Amphipathic polychelating compounds and methods of use |
US5652339A (en) * | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
DE4416166C2 (de) * | 1994-05-06 | 1997-11-20 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen |
US5948756A (en) * | 1995-08-31 | 1999-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Therapeutic lipoprotein compositions |
US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
-
1997
- 1997-10-02 US US08/942,597 patent/US6287590B1/en not_active Expired - Fee Related
-
1998
- 1998-09-28 PT PT98950743T patent/PT1019025E/pt unknown
- 1998-09-28 EP EP98950743A patent/EP1019025B1/de not_active Expired - Lifetime
- 1998-09-28 RU RU2000111523/15A patent/RU2224506C2/ru not_active IP Right Cessation
- 1998-09-28 CN CNB988118181A patent/CN100415210C/zh not_active Expired - Fee Related
- 1998-09-28 AU AU96715/98A patent/AU749344B2/en not_active Ceased
- 1998-09-28 WO PCT/US1998/020330 patent/WO1999017740A1/en active IP Right Grant
- 1998-09-28 PL PL339654A patent/PL196579B1/pl not_active IP Right Cessation
- 1998-09-28 CA CA002305704A patent/CA2305704C/en not_active Expired - Fee Related
- 1998-09-28 HU HU0003930A patent/HUP0003930A3/hu unknown
- 1998-09-28 DK DK98950743T patent/DK1019025T3/da active
- 1998-09-28 KR KR1020007003586A patent/KR100588241B1/ko not_active IP Right Cessation
- 1998-09-28 AT AT98950743T patent/ATE260644T1/de not_active IP Right Cessation
- 1998-09-28 DE DE69822176T patent/DE69822176T2/de not_active Expired - Lifetime
- 1998-09-28 UA UA2000042492A patent/UA71551C2/uk unknown
- 1998-09-28 NZ NZ503721A patent/NZ503721A/en not_active IP Right Cessation
- 1998-09-28 ES ES98950743T patent/ES2217591T3/es not_active Expired - Lifetime
- 1998-09-28 EP EP03015963A patent/EP1358874A1/de not_active Withdrawn
- 1998-09-28 JP JP2000514617A patent/JP2001522781A/ja not_active Withdrawn
- 1998-09-28 IL IL13532298A patent/IL135322A/xx not_active IP Right Cessation
-
2000
- 2000-03-31 NO NO20001683A patent/NO329155B1/no not_active IP Right Cessation
- 2000-08-21 US US09/642,363 patent/US6455088B1/en not_active Expired - Fee Related
-
2002
- 2002-08-12 AU AU2002300504A patent/AU2002300504B2/en not_active Ceased
- 2002-09-23 US US10/252,940 patent/US7189411B2/en not_active Expired - Fee Related
-
2007
- 2007-03-08 US US11/683,784 patent/US20070167351A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE260644T1 (de) | Peptid/lipid-komplexbildung durch co- lyophilisation | |
AU2002300504A1 (en) | Peptide/Lipid Complex Formulation by Co-Lyophilization | |
DE69730218D1 (de) | Fusogene liposomen | |
BG103712A (en) | Lipophilic inert gas-containing medicamentous preparation | |
ATE368053T1 (de) | Antimikrobielle peptide | |
ES2149149T1 (es) | Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion. | |
DE60144543D1 (de) | Oral verabreichte Peptide zur Linderung von Atherosklerose | |
BR0205983A (pt) | fármacos peptìdicos antiangiogênicos | |
NO990276L (no) | Ultralydavbildning av lever | |
ATE396204T1 (de) | Peptide als antiangiogene arzneimittel | |
PT975329E (pt) | Complexos de lipidos e lipossomas de complexos de platina altamente insoluveis | |
ATE322255T1 (de) | Polyamid-oligomere | |
ATE326981T1 (de) | Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
CA2181590A1 (en) | Peptomers with enhanced immunogenicity | |
GR3021660T3 (en) | Anticoagulant peptides | |
ATE466871T1 (de) | Biologisch aktive peptide | |
AU1087199A (en) | Human vesicle membrane protein-like proteins | |
ES2151970T3 (es) | Peptidos dotados de actividad anti-inflamatoria. | |
WO2002030975A3 (en) | Antifungal peptides | |
RU97113033A (ru) | Инсектицидные белковые токсины из photorhabdus | |
DE69707690D1 (de) | Neue peptide und nootroper wirkstoff | |
ATE102835T1 (de) | Schimaerische peptide fuer die lieferung von neuropeptiden durch die blut-hirn-barriere. | |
TR28011A (tr) | Aritilmis/saf streptogramin ve hazirlanisi. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1019025 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |